COMMUNIQUÉS West-GlobeNewswire

ERYTECH confirme l’orientation stratégique d’eryaspase dans les tumeurs solides et interrompt ses développements dans la Leucémie Aiguë Lymphoblastique (LAL)
24/06/2018
Conférence téléphonique lundi 25 juin à 14h30 (heure de Paris) Concentration du développement sur les indications de tumeurs solides Confirmation du lancement d’un essai randomisé de Phase 2 dans le traitement de [...]
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes Care
24/06/2018
Sotagliflozin, in Combination with Insulin, Decreased A1C Levels and Weight in Adults with Type 1 Diabetes THE WOODLANDS, Texas, June 24, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), today [...]
Phillips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
24/06/2018
ARLINGTON, Va., June 24, 2018 (GLOBE NEWSWIRE) -- Today IMV, part of the Science and Medicine Group, and the leading market research and business intelligence provider to the Imaging industry, announced the category [...]
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care
23/06/2018
Sotagliflozin, in Combination with Insulin, Significantly Decreased A1C Levels and Reduced Weight at 52 Weeks Results Observed at 24 Weeks Persisted at 52 Weeks THE WOODLANDS, Texas, June 23, 2018 (GLOBE NEWSWIRE) -- [...]
Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial
23/06/2018
Orlando, US, 23 June 2018 - Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to [...]
Ozempic® provided greater weight reductions for adults with a baseline BMI of or above 25 kg/m2 than those with lower baseline BMI <25 kg/m2, in a SUSTAIN 7 post-hoc analysis
23/06/2018
Orlando, US, 23 June 2018 - Ozempic ® (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass [...]
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)
23/06/2018
Press Release - No. 17/2018 Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA) Low doses of dasiglucagon effectively counteract low [...]
Tresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycaemia versus insulin glargine U300 in real-world evidence study
23/06/2018
Adults with type 2 diabetes treated with Tresiba ® (insulin degludec injection) had a significant reduction in HbA 1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Orlando, US, 23 June 2018 [...]
Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at the ADA's 78th Scientific Sessions
23/06/2018
Press Release - No. 16/2018 Survey demonstrating underuse of glucagon rescue kits in type 1 diabetes patients to be presented at the ADA's 78th Scientific Sessions T1D Exchange and Dr. Morey Haymond, MD, to present a [...]
MannKind Presents Positive Afrezza® Clinical Data from STAT and AFFINITY Studies at ADA 78th Scientific Sessions
23/06/2018
Poster 1017-P: Afrezza provides improved Time-in-Range on Continuous Glucose Monitoring compared to insulin aspart Poster 102-LB: Hypoglycemia is reduced with use of Afrezza compared to insulin aspart WESTLAKE VILLAGE, [...]
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
23/06/2018
Trial met all primary objectives, demonstrated efficacy and safety and established minimally effective dose of 0.9 mg for ZGN-1061 Patient dosing recently initiated for the 1.8 mg dose cohort Zafgen presenting the Phase [...]
Significant blood sugar improvement with Xultophy® compared to insulin glargine U-100 when used as add-on to oral diabetes medications
23/06/2018
Adults with type 2 diabetes treated with Xultophy ® (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Bagsværd, [...]
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand
23/06/2018
Company surpasses $1M in accepted investments; expects to make significant scientific announcement in the near future CHICAGO, June 23, 2018 (GLOBE NEWSWIRE) -- BIOLIFE4D , a biotech pioneer leveraging advances in [...]
Artificial Intelligence-Powered Sugar.IQ(TM) Diabetes Management App Developed by Medtronic and IBM Watson Health Now Commercially Available
23/06/2018
Real-World Experience Data on Sugar.IQ App Use Presented at the 78th Scientific Sessions of the American Diabetes Association DUBLIN AND CAMBRIDGE - June 22, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical [...]
Healthcare Special Opportunities Fund Announces June 2018 Quarterly Distribution
22/06/2018
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, June 22, 2018 (GLOBE NEWSWIRE) -- (TSX:MDS.UN) – LDIC Inc. (the “ Manager ”), the manager of Healthcare Special [...]
Analogic Announces Completion of Acquisition by an Affiliate of Altaris Capital Partners
22/06/2018
Investment by Altaris Supports Analogic’s Capabilities to Deliver Innovative Solutions and Service to its Customers PEABODY, Mass. and NEW YORK, June 22, 2018 (GLOBE NEWSWIRE) -- Analogic Corporation (NASDAQ:ALOG) (“the [...]
Altimmune Restructures Financing Agreement
22/06/2018
GAITHERSBURG, Md., June 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has entered into an agreement [...]
Imagin Provides Further Detail on Kilmer Lucas Engagement
22/06/2018
VANCOUVER, British Columbia and BOSTON, June 22, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE:IME) (OTC PINK:IMEXF) (Frankfurt:DPD2) (Stuttgart:DPD2) (“Imagin” or the “Company”) is pleased to provide, in addition to its [...]
DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel
22/06/2018
Montrouge, France, June 22, 2018 DBV Technologies Announces Results of its 2018 Ordinary and Extraordinary General Meeting and the Appointment of Joan Schmidt as Executive Vice President, General Counsel Shareholders [...]

Pages